The Rising Influence of Rising Affluence

[DewDiligence]

ELAN 3Q19 results:

https://investor.elanco.com/investors/press-releases/press-release-details/2019/Elanco-Animal-Health-Reports-Third-Quarter-Results/default.aspx

The upper bound of the 2019-guidance range for non-GAAP EPS was lowered slightly; the new non-GAAP EPS range is $1.04-1.08 (vs the prior range of $1.04-1.10).

3Q19 results and forward guidance do not include Bayer’s animal health business, which ELAN is in the process of acquiring (#msg-150629685).

The stock is -4% in PM trading.